Sepsis management and antiendotoxin therapy after nebacumab. A reappraisal.
Hurley
J C
JC
Division of Infectious Diseases, Children's Hospital and Medical Center, Seattle, Washington.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002986:Clinical Trials as Topic; D003907:Dexamethasone / Q000627:therapeutic use; D004731:Endotoxins / Q000276:immunology*; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D008775:Methylprednisolone / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004731:Endotoxins; D003907:Dexamethasone; C068069:nebacumab; D008775:Methylprednisolone